A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects

NCT04796831 PHASE1 COMPLETED Results posted

Quizartinib, a selective FLT3 inhibitor, is being developed as a treatment for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The absolute oral bioavailability of quizartinib has not yet been studied. This study is designed to estimate quizartinib bioavailability of quizartinib following oral and intravenous (IV) administration.

Details

Lead sponsor	Daiichi Sankyo
Phase	PHASE1
Status	COMPLETED
Enrolment	8
Start date	Mon Apr 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jun 11 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Healthy Subjects

Interventions

• Quizartinib dihydrochloride
• 14C-Quizartinib solution for infusion

Countries

United Kingdom